Follow us for updates
© 2022
Read the Story →

Sinovac Can Now Be Given to Kids as Young as 6: FDA

China-made COVID vaccine cleared for emergency use.
by Erwin Colcol
17 hours ago
Photo/s: Pasig City Public Information Office/Handout

The Philippines' Food and Drug Administration on Tuesday said it had cleared the COVID-19 vaccine manufactured by China's Sinovac for emergency use on minors as young as six years old as the government expands inoculation to more populations.

CoronaVac is the third COVID-19 vaccine authorized by the FDA to be used for the pediatric age group after Pfizer and Moderna. It was recommended to be administered in two doses four weeks apart.

"Based on the evidence submitted which includes clinical trials and real-world effectiveness data, CoronaVac was found to have acceptable immunogenicity and safety profile in pediatric groups," the FDA said in a statement.

"The assessment done ensured that the benefits outweigh the known and potential risks of the product based on the totality of evidence presented and available data," it added.

With COVID-19 vaccines now available for young children, the FDA reminded parents and guardians to have their kids vaccinated by healthcare providers who are trained to recognize and manage adverse reactions.

Continue reading below ↓

As of March 13, over 64 million Filipinos have been fully vaccinated against COVID-19, of which more than 11 million have received their booster shots, the Department of Health said.


COVID Vaccination of Kids 5-11 Starts, Here's What You Need to Know

GUIDE: COVID Vaccines for Kids Aged 5 to 11, What You Need to Know

How to Prepare Children Afraid of Needles for a COVID-19 Vaccine

Continue reading below ↓
Recommended Videos

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.